// App-Quantinova.ai

451 : Effect of Hepatic Venous Pressure Gradient (HVPG) Changes on Cirrhosis Decompensation in Patients with Clinically‐Significant Portal Hypertension (CSPH)

Researchers

Presenter

  • Jordan Sack

Principal Investigators

  • Guadalupe Garcia-Tsao

  • Cristina Ripoll

  • Yanhong Deng

  • Maria Ciarleglio

  • David Patch

  • Norman D. Grace

  • Angels Escorsell

  • Jaime Bosch

  • Roberto J. Groszmann

Medical Centers

  • Department of Medical Oncology, Yale University School of Medicine, New Haven, CT

  • Digestive Disease, Yale University School of Medicine, New Haven, CT

  • Digestive Diseases Section, VA-CT Healthcare System, West Haven, CT

  • Department of Biostatistics, Yale School of Public Health, New Haven, CT

  • The Royal Marsden Hospital, London, United Kingdom

  • Brigham and Women's Hospital, Brookline, MA

  • Intensive Care Unit, Hospital Clinic, Barcelona, Spain

Locations

  • United States

  • United Kingdom

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Hepatic encephalopathy

  • Portal Hypertension

  • Encephalopathy

  • Hypertension

  • Cirrhosis

Biomarkers

  • Hepatic Venous Pressure Gradient

Drug/Treatment

  • Timolol

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved